Exhibit 99.1 Humacyte Third Quarter 2024 Financial Results and Business Update - FDA review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma is ongoing - - Results from the V007 Phase 3 clinical trial of the ATEV in arteriovenous (AV) access for hemodialysis patients presented at American Society of Nephrology's Kidney Week 2024 - - Long-term results from the humanitarian program where the ATEV was used to treat vascular injuries suffered during the Ukraine conflict wer ...

- FDA review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma is ongoing - - Results from the V007 Phase 3 clinical trial of the ATEV in arteriovenous (AV) access for hemodialysis patients presented at American Society of Nephrology’s Kidney Week 2024 - - Long-term results from the humanitarian program where the ATEV was used to treat vascular injuries suffered during the Ukraine conflict were presented at the U.S. Department of Defense’s foremost scientific meeting - - ...

DURHAM, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the third quarter ended September 30, 2024, on Friday, November 8, 2024. Management will host a webcast and conference call at 8:30 a.m. ET to discuss recent corporate updates from its acellular tissue engineered vessel (ATEV) programs. Title:Humacyte Third Quar ...

SAN FRANCISCO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ: HUMA), a biotechnology company focused on developing acellular tissue engineered vessels, has faced significant setbacks in recent months due to regulatory scrutiny from the U.S. Food and Drug Administration (FDA). The company's stock price has plummeted following disclosures of FDA violations at its manufacturing facility and delays in the approval process for its flagship product. Hagens Berman urges investors in Humacyte who suffere ...

– ATEV™ demonstrated superiority at six and 12 months (co-primary endpoints) compared to autogenous fistula, the current standard of care for hemodialysis access – - ATEV also showed superior function and patency in female, obese and diabetic patients, subgroups with historically poor outcomes with autogenous fistula procedures - DURHAM, N.C., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered hum ...

NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) on behalf of Humacyte stockholders. Our investigation concerns whether Humacyte has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On August 9, 2024, Humacyte disclosed that the U.S. Food and Drug Adm ...

Humacyte, Inc. (HUMA) closed the most recent trading day at $5.82, moving +1.75% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.22%. On the other hand, the Dow registered a loss of 0.33%, and the technology-centric Nasdaq increased by 0.76%.The the stock of company has risen by 4.86% in the past month, leading the Medical sector's loss of 3.79% and the S&P 500's gain of 1.47%.Analysts and investors alike will be keeping a close eye on the performance of Humacyte, Inc. in ...

SAN FRANCISCO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- On October 17, 2024, the U.S. Federal Food & Drug Administration (“FDA”) published its April 5, 2024 report addressed to Humacyte’s Chief Operating Officer (Heather Prichard) detailing problems with Humacyte’s facilities. The FDA’s April 5, 2024 report submitted to Prichard appears to potentially contradict her assurances to investors at an earnings call on May 12, 2024 in response to analyst questions. Hagens Berman urges investors in Humacyte, Inc. (NASDAQ: ...

In the latest market close, Humacyte, Inc. (HUMA) reached $5.70, with a +0.53% movement compared to the previous day. This change outpaced the S&P 500's 0.76% loss on the day. Meanwhile, the Dow lost 0.75%, and the Nasdaq, a tech-heavy index, lost 1.01%. Shares of the company have appreciated by 7.39% over the course of the past month, outperforming the Medical sector's loss of 3.35% and the S&P 500's gain of 4.31%. Market participants will be closely following the financial results of Humacyte, Inc. in its ...

DURHAM, N.C., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that its late-breaking abstract on the V007 Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV™) in arteriovenous access for patients with end-stage renal disease was accepted for an oral presentation at the American Society of Nephrology's (ASN) Kidney Week 2024. The la ...